Zydus Cadila gets Mexican nod for clinical trials of Pegylated Interferon alpha-2b

The treatment option emerged after the publication of two recent peer-reviewed research articles. The first one by Ogando et al (Journal of General Virology, June 2020) at Leiden University Medical Center, Netherlands showed evidence of a direct anti-viral effect of Pegylated Interferon-alpha against novel Coronavirus. The study demonstrated that Pegylated Interferon was able to completely neutralize the SARS-CoV-2 virus in vitro. The second by Zhou et al (Frontiers in Immunology, May 2020) from a group of universities in China, Australia and Canada retrospectively analyzed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alpha-2b showed a significant reduction in the duration of virus shedding period and even in levels of the inflammatory cytokine, IL6.

How Interferon Alpha 2b works

When the human body contracts an infection due to a viral attack, it produces a group of molecules called Type 1 interferons as the first line of defense. Interferon-alpha is one such Type 1 Interferon molecule, that not only slows down the viral replication but also helps activate the two arms of our immune system – Innate, for the immediate killing of the virus and Adaptive, for long-lasting immunity.

To make it more effective, the molecule is coupled with polyethylene glycol to produce a new molecule called, Pegylated Interferon-alpha, which has the same functionality as Interferon-alpha but remains in the body longer and therefore requires only once-a-week injection, thus providing a much better efficacy profile.

Zydus has been commercially manufacturing Pegylated Interferon alpha-2b under the brand name, PegiHepTM, since 2011 for the treatment of Hepatitis B and C with 1.5 lac doses being administered. PegiHepTM is not yet licensed or approved for the treatment of COVID-19.

Also Read: Zydus Cadila Aims To Complete Trial Of COVID-19 Vaccine By March